Completed PHASE1 INTERVENTIONAL 7-arm NCT02231931

Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin

Relative Bioavailability of a Single Oral Dose of Digoxin, Furosemide, Metformin, and Rosuvastatin Given Alone and All Together as a Cocktail, and Investigation of the Effect of Increased Doses of Metformin or Furosemide on Relative Bioavailability of the Other Cocktail Compounds in Healthy Male Subjects

Sponsor: Boehringer Ingelheim

Conditions Healthy

Interventions Digoxin Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin Furosemide Metformin hydrochloride Rosuvastatin

Updated 6 times since 2017 Last updated: Oct 23, 2023 Started: Sep 1, 2014 Primary completion: Jan 1, 2015 Completion: Jan 1, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Boehringer Ingelheim leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Nov 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Nov 2023 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Biberach, Germany